3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
4
Observational
1
Sponsor
Conditions
Recurrence
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell
2
Neoplasms
1
Multiple Myeloma
1
Inflammation
1
Hematologic Neoplasms
1
Drug-Related Side Effects and Adverse Reactions
1
Cytopenia
1
Burkitt Lymphoma
1
Interventions
Surveys and Questionnaires
86
Blood Specimen Collection
58
Interviews as Topic
28
Observation
15
Data Collection
15
Radiotherapy
12
Watchful Waiting
11
Magnetic Resonance Spectroscopy
11
Hematologic Tests
11
Exercise
11
Drug Therapy
11
Quality of Life
9
Biopsy
8
Specimen Handling
7
Therapeutics
6
Restraint, Physical
6
Magnetic Resonance Imaging
6
Focus Groups
6
pembrolizumab
5
Standard of Care
5
Rivaroxaban
5
Phlebotomy
5
Nivolumab
5
Lapatinib
5
Immune Checkpoint Inhibitors
5
atezolizumab
4
apixaban
4
Trastuzumab
4
Patient Reported Outcome Measures
4
Palliative Care
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Neoplasms
×
Immunotherapy, Adoptive
×
Clear all
NCT04279470
2023-04-13
CARTABLE
Groupe Hospitalier Pitie-Salpetriere
Completed
100,000 enrolled